Meeting
2020 ASCO Virtual Scientific Program
Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
Authors
Ramon Jin
Washington University School of Medicine, St. Louis, MO
Ramon Jin , Haeseong Park , Andrea Wang-Gillam , Rama Suresh , Caron E. Rigden , Manik A. Amin , Benjamin R. Tan Jr., Katrina Pedersen , Kian-Huat Lim , Nikolaos Trikalinos , Abhi Acharya , Megan Copsey , Katie Navo , Ashley Morton , Feng Gao , A. Craig Lockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01928290
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4532)
DOI
10.1200/JCO.2020.38.15_suppl.4532
Abstract #
4532
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
First Author: Haeseong Park
Poster
2015 Gastrointestinal Cancers Symposium
FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).
First Author: Albert C. Lockhart
Poster
2022 ASCO Annual Meeting
Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
First Author: Angela Damato
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang